Wegovy Tablets Vs Injections

If you have been searching for a clinically proven weight loss solution in the UK and stumbled across the term WTI — which stands for Weight Treatment Indication — you are likely already aware of the growing interest in Wegovy tablets and injectable semaglutide treatments. Wegovy has transformed the landscape of obesity medicine since its approval, and in 2026 it remains one of the most talked-about and evidence-backed options available for adults who have struggled to achieve meaningful, sustainable weight loss through diet and exercise alone.

Quick Summary

Wegovy tablets represent a significant step forward in medically supervised weight management, offering clinically meaningful results when used correctly alongside lifestyle changes. Understanding how semaglutide works, who qualifies, and what to expect from treatment can help you make an informed decision about whether this therapy is right for you.

• Wegovy is a semaglutide-based weight loss treatment approved by the MHRA for use in the UK.
• It works by mimicking the GLP-1 hormone to reduce appetite and slow gastric emptying.
• The WTI (Weight Treatment Indication) refers to the clinical criteria used to determine who qualifies for Wegovy treatment.
• Clinical trials have shown adults can lose up to 15% of their body weight over 68 weeks.
• Treatment must be prescribed and monitored by a qualified UK healthcare professional.

Table of Contents

1. What Is WTI and How Does It Relate to Wegovy?
2. How Wegovy Tablets Work to Support Weight Loss
3. Who Qualifies for Wegovy in the UK?
4. Wegovy Dosing Schedule and Treatment Timeline
5. Common Side Effects and How to Manage Them
6. Wegovy Compared to Other UK Weight Loss Treatments
7. Key Takeaways
8. When to Seek Professional Advice
9. Scientific References
10. FAQs

What Is WTI and How Does It Relate to Wegovy Tablets?

WTI stands for Weight Treatment Indication, a clinical term used to describe the criteria that determine whether a patient is eligible for a prescription weight loss medication such as semaglutide. In plain terms, WTI is the framework healthcare providers use to assess whether pharmacological intervention — like Wegovy tablets — is appropriate for an individual. This matters enormously for anyone who has spent years dieting and exercising without achieving lasting results, because it offers a structured, medically validated pathway rather than yet another unsupported weight loss trend.

Within the UK's NHS and private prescribing system, the WTI criteria for Wegovy generally requires a body mass index (BMI) of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as type 2 diabetes, high blood pressure, or obstructive sleep apnoea. This means the treatment is specifically targeted at people for whom excess weight is creating genuine clinical risk — not those seeking cosmetic or minor changes. The Wegovy tablets system ensures that medication is prescribed responsibly and in line with NICE guidance.

Understanding WTI is particularly useful if you have been turned away from NHS weight management services due to long waiting lists, which remain a widespread problem across England in 2026. Many people now turn to regulated private online pharmacies where qualified prescribers can assess WTI eligibility and, where appropriate, initiate treatment quickly. If you are considering Mounjaro weight loss injections (tirzepatide) or semaglutide-based treatments, understanding your WTI status helps you have a more productive conversation with your prescriber.

• WTI confirms clinical need for pharmacological weight management.
• BMI thresholds are 30+ or 27+ with a weight-related comorbidity.
• Prescribers use WTI to match patients to the most appropriate treatment.
• Private prescribing pathways allow faster access when NHS queues are long.

How Wegovy Tablets Work to Support Weight Loss

Semaglutide, the active ingredient in Wegovy, belongs to a class of medicines known as GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone produced naturally in the gut after eating. It plays a key role in regulating blood sugar, stimulating insulin release, slowing the rate at which food leaves the stomach, and importantly — signalling the brain that you are full. By mimicking this hormone at pharmacologically meaningful levels, Wegovy tablets help to reduce appetite, lower calorie intake, and ultimately promote fat loss in a way that does not rely solely on willpower.

The mechanism is important to understand because it explains why semaglutide works differently from older-generation weight loss pills. Rather than acting as a stimulant or blocking fat absorption, it works through the body's own hormonal signalling system. This makes it far more physiologically aligned with how hunger and satiety actually function. Many patients describe a notable reduction in food cravings and a reduced interest in high-calorie foods within the first few weeks of starting treatment — a phenomenon some clinicians refer to as "food noise reduction."

Research published through the STEP (Semaglutide Treatment Effect in People with obesity) clinical programme, which was a landmark series of international trials, demonstrated that adults receiving semaglutide 2.4mg weekly lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% in the placebo group. These results have been consistently replicated and represent some of the strongest clinical evidence for any non-surgical weight loss intervention currently available. The data supports using Wegovy tablets as a meaningful, evidence-based intervention rather than a shortcut.

• Mimics the GLP-1 hormone to reduce hunger signals from the brain.
• Slows gastric emptying, helping you feel full for longer after meals.
• Reduces food cravings and overall calorie intake without requiring strict deprivation.
• Clinically proven in large-scale trials to deliver 12–15% average body weight reduction.
• Works best when combined with a balanced diet and regular physical activity.

Who Qualifies for Wegovy in the UK?

Eligibility for Wegovy is governed by MHRA approval criteria and, in NHS settings, NICE guidelines. To receive a prescription, patients must meet specific clinical thresholds that align with WTI criteria. A BMI of 30 kg/m² or higher qualifies most adults without additional conditions. Those with a BMI between 27 and 29.9 may still qualify if they have at least one weight-related health comorbidity such as pre-diabetes, cardiovascular disease, dyslipidaemia, or obstructive sleep apnoea. It is worth noting that NICE guidance updated in recent years has expanded access, and more people than ever are now qualifying through both NHS and private routes.

Importantly, Wegovy is not appropriate for everyone. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It is also not recommended during pregnancy or breastfeeding. Prescribers will take a full medical history before initiating treatment, and patients will be assessed for any medicines that might interact with semaglutide. The full prescribing process is therefore thorough and designed to protect patient safety at every step.

For those who do not yet meet the BMI threshold but are concerned about their weight, there are other options worth exploring. Products such as XLS Medical Weight Loss Plus tablets and Orlos (orlistat) 60mg weight loss aid are available for those who fall just below the prescription threshold and want to take proactive steps while working with a healthcare professional to manage their weight. These options complement lifestyle changes and can support your overall weight management plan.

• BMI of 30+ qualifies most adults for Wegovy without additional conditions.
• BMI 27–29.9 qualifies with at least one weight-related health comorbidity.
• Thyroid cancer history and pregnancy are absolute contraindications.
• Full medical history review is always required before prescribing.
• Private prescribing offers an accessible alternative when NHS pathways are delayed.

Wegovy Dosing Schedule and Treatment Timeline

One of the most common points of confusion for new patients is understanding how Wegovy is dosed and why it takes several months to reach the full therapeutic level. The answer lies in the slow titration schedule, which is specifically designed to reduce gastrointestinal side effects and allow your body to adapt to increasing concentrations of semaglutide. Rushing the dose escalation is one of the most frequently reported reasons for poor tolerability, and it is why following the prescribed schedule precisely is so important.

Treatment begins at 0.25mg once weekly for the first four weeks. This is a sub-therapeutic dose intended purely for tolerability. From there, the dose doubles to 0.5mg weekly for another four weeks, then progresses through 1.0mg, 1.7mg, and finally reaches the maintenance dose of 2.4mg once weekly at week 17. Some prescribers will allow patients to remain at 1.7mg if they achieve adequate results or experience difficulty tolerating 2.4mg. The full benefits of Wegovy tablets are typically seen from week 12 onwards, with maximum results occurring after 52 to 68 weeks of consistent treatment.

Current formulations of Wegovy in the UK are delivered via a pre-filled auto-injector pen administered subcutaneously — typically into the abdomen, thigh, or upper arm. There is considerable ongoing research into oral semaglutide formulations, and whilst oral semaglutide is already licensed for type 2 diabetes management under the brand name Rybelsus, the oral formulation specifically indicated for weight loss at the higher 2.4mg equivalent dose is expected to become more widely available following regulatory decisions anticipated in 2026. This development would be transformative for patients with needle phobia who have been reluctant to start injectable treatment.

Week	Dose of Semaglutide	Frequency	Purpose
Weeks 1–4	0.25mg	Once weekly	Tolerability initiation dose
Weeks 5–8	0.5mg	Once weekly	Gradual dose escalation
Weeks 9–12	1.0mg	Once weekly	Mid-range escalation
Weeks 13–16	1.7mg	Once weekly	Near-maintenance escalation
Week 17 onwards	2.4mg	Once weekly	Full maintenance therapeutic dose

• Always follow the slow titration schedule — do not skip steps.
• Administer the injection on the same day each week for consistency.
• Rotate injection sites to prevent lipohypertrophy (localised fat thickening).
• Store Wegovy pens in a refrigerator between 2°C and 8°C.
• Contact your prescriber if you need to delay a dose or experience severe side effects.

Common Side Effects and How to Manage Them

Like all prescription medicines, Wegovy carries a risk of side effects. The most frequently reported ones are gastrointestinal in nature, which is consistent with how the drug works — slowing digestion naturally creates some disruption to the gut during the adjustment period. Most side effects are mild to moderate, tend to peak during dose escalation phases, and improve significantly as the body adapts over several weeks. Knowing what to expect in advance means patients are far less likely to discontinue treatment prematurely when symptoms are actually temporary and manageable.

Nausea is by far the most commonly reported side effect, affecting up to 44% of participants in the STEP trials. Vomiting, diarrhoea, constipation, and abdominal discomfort are also reported with notable frequency. Practical strategies that genuinely help include eating smaller meals more frequently, avoiding fatty or spicy foods during dose escalation weeks, staying well hydrated, and taking your injection at night so that any immediate nausea occurs during sleep. Some patients also find that ginger tea or dry crackers help settle their stomach in the early weeks of treatment.

Less common but more serious side effects include pancreatitis, gallbladder disease, and in rare cases a heart rate increase. These are reasons why ongoing prescriber monitoring is essential, particularly in the first six months. If you experience severe abdominal pain that radiates to your back, persistent vomiting that prevents you from keeping food down, or notice yellowing of your skin or eyes, you should seek medical attention immediately. Patients on other medications — particularly those for blood sugar management such as insulin or sulfonylureas — need close monitoring as Wegovy can enhance their glucose-lowering effect. For general digestive support between consultations, speaking to your pharmacist about appropriate remedies is always a sensible step.

• Nausea is the most common side effect and typically peaks during dose increases.
• Eat smaller, blander meals and stay hydrated to reduce gastrointestinal discomfort.
• Avoid lying down immediately after eating to minimise nausea and reflux symptoms.
• Report any severe or persistent abdominal pain to your prescriber immediately.
• Side effects almost always reduce significantly once the maintenance dose is reached.

Wegovy Compared to Other UK Weight Loss Treatments

The weight loss medication landscape in the UK has become considerably more varied in recent years, and patients now have access to a range of prescription and over-the-counter options. Understanding how Wegovy sits within this broader context is important, particularly for those who are weighing up their options or who may not yet meet the eligibility threshold for semaglutide. Each treatment works through a different mechanism, carries different risk profiles, and suits different clinical situations.

Orlistat (available both over the counter as Orlos and on prescription as Xenical) works by blocking fat absorption in the gut rather than suppressing appetite. It requires adherence to a low-fat diet to avoid unpleasant side effects and produces more modest results — typically around 5–7% body weight reduction over 12 months. Tirzepatide (Mounjaro) is arguably the closest competitor to Wegovy, acting on both GLP-1 and GIP receptors simultaneously and producing even greater average weight loss in clinical trials. For those seeking alternatives that do not require a prescription, options such as XLS Medical Direct Fat Binder sachets offer a non-prescription approach for lower-risk patients.

What makes Wegovy stand out is the breadth and quality of its clinical evidence base. The STEP trials are among the most rigorous obesity clinical programmes ever conducted, and the results are consistent across diverse patient populations. In terms of NHS commissioning, Wegovy was recommended by NICE in 2023 specifically for specialist weight management settings, reflecting the confidence of UK regulators in its benefit-risk profile. Patients choosing between treatments should always do so in consultation with a prescriber who can assess their complete clinical picture. The right treatment is rarely a matter of which is "best" in absolute terms — it is which is best for you as an individual.

• Wegovy produces greater average weight loss than orlistat or over-the-counter aids.
• Mounjaro (tirzepatide) may produce even greater results due to its dual-receptor action.
• Over-the-counter options suit patients below the prescription eligibility threshold.
• NICE recommends Wegovy in specialist settings based on robust clinical evidence.
• Always discuss your individual medical history with a prescriber before choosing a treatment.

Key Takeaways

• WTI (Weight Treatment Indication) is the clinical framework that determines eligibility for weight loss medications like Wegovy.
• Wegovy works by mimicking the GLP-1 hormone, reducing hunger and slowing digestion to support sustainable fat loss.
• The full maintenance dose of 2.4mg is reached gradually over 17 weeks to minimise gastrointestinal side effects.
• Clinical trials show up to 15% average body weight reduction over 68 weeks, making it one of the most effective non-surgical weight loss treatments available.
• Treatment must always be prescribed and supervised by a qualified UK healthcare professional to ensure safety and appropriate monitoring.

When to Seek Professional Advice

Weight loss treatment is not one-size-fits-all, and knowing when to escalate your concerns to a healthcare professional is just as important as following your treatment plan. You should speak to your prescriber or a qualified pharmacist if you experience severe or persistent nausea, vomiting, or abdominal pain during treatment, especially if it is preventing you from eating or drinking. These symptoms may indicate a more serious reaction that requires dose adjustment or temporary pause of treatment.

You should also seek advice if you notice no meaningful weight loss after 16 weeks on the maintenance dose, as this may indicate that an alternative treatment is more appropriate for your biology. Changes in your other medications, the development of new health conditions, or a planned pregnancy are all situations where your prescriber needs to be informed promptly. If you are unsure whether Wegovy is suitable for you in the first place, an online consultation with a regulated prescriber is a fast, convenient, and fully confidential way to get a personalised clinical assessment without waiting for an NHS referral.

Additionally, if you have been taking Wegovy and experience symptoms of low blood sugar — such as shakiness, sweating, confusion, or palpitations — particularly if you are also on diabetes medications, this warrants immediate medical attention. Thyroid lumps, difficulty swallowing, or persistent hoarseness should also be reported, as these require investigation to rule out rare but serious thyroid-related side effects. Do not stop treatment abruptly without speaking to your prescriber, as this can lead to rapid weight regain that is difficult to reverse. Consider also discussing your overall nutritional status with your prescriber, as reduced appetite from treatment may affect nutrient intake — a thyroid test may be appropriate if you have related concerns.

Frequently Asked Questions

How long does it take for Wegovy tablets to start working?

Wegovy tablets begin working from the first dose by reducing appetite, but meaningful weight loss typically becomes noticeable after four to eight weeks of consistent use alongside a reduced-calorie diet and regular physical activity, with more significant results often seen after twelve to sixteen weeks at the maintenance dose.

Is Wegovy safe to use long-term in the UK?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified UK healthcare professional. Clinical trial data, including the STEP programme, supports its safety profile over periods of up to two years, though regular medical reviews are recommended to assess ongoing suitability and monitor for any side effects.

Can you take Wegovy tablets with other weight loss medications?

Wegovy tablets should not be combined with other GLP-1 receptor agonists or injectable semaglutide products, as this increases the risk of side effects. Always inform your prescriber of all medications you are taking, including over-the-counter weight loss aids, so they can assess safety and potential interactions before starting treatment.

What is the correct dose of Wegovy tablets for weight loss?

The standard Wegovy dosing schedule begins at 0.25mg once weekly for the first four weeks, gradually increasing every four weeks up to the maintenance dose of 2.4mg once weekly. This slow titration approach is designed to minimise gastrointestinal side effects and allow the body to adjust to semaglutide treatment.

Scientific References

1. NICE Technology Appraisal TA875 — Semaglutide for managing overweight and obesity (2023). National Institute for Health and Care Excellence.
2. Wegovy 2.4 mg solution for injection — Summary of Product Characteristics. Electronic Medicines Compendium (eMC), MHRA Approved.
3. Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity — STEP 1 trial. The Lancet.